Clinical trials: Pancreas Tumor
Sarcoma, Carcinoma
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
- Conditions
- Sarcoma, Carcinoma, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT05860374
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer, Pancreatic Cancer
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite
- Trial name
- PROACC-1 (NCT05546476)
- Testing
- ponsegromab
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Pancreatic Cancer
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase.
- Trial name
- NCT05827796
- Testing
- IN10018, Albumin-Bound Paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Advanced Solid Tumor, Breast Cancer
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.
- Conditions
- Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Ovary Cancer
- Trial name
- NCT05465590
- Testing
- MB1707
- Sponsor
- Mainline Biosciences, Inc.
Pancreatic Ductal Adenocarcinoma
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or…
- Trial name
- STOP-PC (NCT06079346)
- Testing
- OT-101, mFOLFIRINOX
- Where
- 2 sites in United States
- Volunteers
- 455 people
- Sponsor
- Oncotelic Inc.
Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to determine whether S-1 is effective in slowing tumor activity in participants with locally advanced or metastatic pancreatic cancer who have not had chemotherapy.
- Trial name
- NCT00651742
- Testing
- S-1
- Volunteers
- 28 people
- Sponsor
- Taiho Oncology, Inc.
Pancreatic Adenocarcinoma
A Study of MLN0264 in Patients With Pancreatic Cancer
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.
- Trial name
- NCT02202785
- Testing
- MLN0264
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Pancreatic Cancer
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
This is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy.
- Trial name
- NCT07784374
- Testing
- GFH375, GFH276, GFS202A
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Cancer of the Pancreas, Pancreatic Cancer
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)
This is a case-control study to clinically validate the performance of PancreaSure, a protein biomarker test, to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired…
- Conditions
- Cancer of the Pancreas, Pancreatic Cancer, Pancreas Neoplasms, Pancreatic Carcinoma Stage I
- Trial name
- VERIFI (NCT06947395)
- Testing
- PancreaSure
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Immunovia, Inc.
Metastatic Pancreatic Adenocarcinoma
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
The purpose of this study is to determine whether CO-1.01 is safe and effective for treating metastatic pancreatic cancer that did not respond to gemcitabine.
- Trial name
- NCT01233375
- Testing
- CO-1.01
- Where
- 13 sites in United States
- Volunteers
- 19 people
- Sponsor
- Clovis Oncology, Inc.
Pancreatic Cancer
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
This is the first study investigating the safety of 32P BioSilicon in patients with advanced,unresectable pancreatic cancer who are also receiving standard intravenous gemcitabine chemotherapy.
- Trial name
- NCT00346281
- Testing
- 32P BioSilicon
- Where
- 2 sites in Singapore, United Kingdom
- Volunteers
- 15 people
- Sponsor
- pSiMedica Limited
KRAS G12D Mutation, Advanced Solid Cancer
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
- Trial name
- NCT07023731
- Testing
- ARV-806
- Where
- 14 sites in United States
- Volunteers
- 76 people
- Sponsor
- Arvinas Inc.
Ovarian Neoplasms, Endometrial Neoplasms
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06400472
- Testing
- Sofe-M, bevacizumab, carboplatin
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 575 people
- Sponsor
- Eli Lilly and Company
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum…
- Trial name
- POLO (NCT02184195)
- Testing
- Olaparib
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with or without chemotherapy and chemoradiation.
- Trial name
- NCT00614601
- Testing
- HyperAcute(R)-Pancreatic Cancer Vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NewLink Genetics Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.